MSD held responsible for third‑party email banner missing generic name (Maxalt) – AUTH/1795/2/06

📅 2006 | 🖉 Dr Anzal Qurbain
📊

Key facts

CaseAUTH/1795/2/06
PartiesGeneral Practitioner v Merck Sharp & Dohme
MaterialeMIMS email promoting an online presentation/edetail for Maxalt (rizatriptan)
Main issueMost prominent “Maxalt” in banner not accompanied by non-proprietary name immediately adjacent
Third-party involvementAgency and publications company distributed email; publications company added standard intro/banner without MSD’s knowledge
Applicable Code year2003 (case considered under 2006 Code; no difference for Clause 4.3)
BreachClause 4.3
SanctionUndertaking received
Complaint received05/06 February 2006 (reported as 6 February 2006 in the report)
Case completed05/06 March 2006 (reported as 6 March 2006 in the report)
AppealNo appeal

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • A general practitioner received an email from eMIMS, marked “In association with MSD”, promoting an online presentation/edetail about Maxalt (rizatriptan).
  • The top banner read “eMIMS MAXALT Presentation: appropriate use in migraine”.
  • The complainant alleged the most prominent use of “Maxalt” (in the banner) was not accompanied by the non-proprietary name.
  • MSD said distribution was arranged via an agency and a publications company; MSD approved its own content (the main body) but did not know the publications company would add an introductory section (including the banner) and had not seen the final email.
  • The Panel considered the email was arranged on MSD’s behalf and promoted MSD’s product, so MSD was responsible for the whole email.
⚖️

Outcome

  • Breach ruled: the non-proprietary name did not appear immediately adjacent to the most prominent display of the brand name in the banner.
  • Clause breached: Clause 4.3.
  • No appeal.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training